The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?
- PMID: 26215959
- DOI: 10.1200/JCO.2015.62.3165
The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?
Comment in
-
Reply to K. Lu.J Clin Oncol. 2015 Oct 1;33(28):3222-3. doi: 10.1200/JCO.2015.62.4692. Epub 2015 Jul 27. J Clin Oncol. 2015. PMID: 26215948 No abstract available.
-
Reply to K. Lu.J Clin Oncol. 2015 Oct 1;33(28):3222. doi: 10.1200/JCO.2015.62.4684. Epub 2015 Jul 27. J Clin Oncol. 2015. PMID: 26215954 No abstract available.
Comment on
-
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.J Clin Oncol. 2015 Mar 1;33(7):723-31. doi: 10.1200/JCO.2014.56.5119. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624429 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical